ATRC · AtriCure, Inc.

The thesis

AtriCure's profit-led re-rating now rests on the third-quarter report, scheduled for 3 November 2026 according to a financial-news aggregator citing the company's announcement. The shares closed at $61.08 on 26 October 2026, a 52-week high, and the report has to show revenue that supports a price above the average analyst target recorded in September.

The business facts are unchanged since the 23 July 2026 second-quarter release: revenue of $153.6 million, up 12.8% year over year, net income of $9.0 million, and fiscal 2026 revenue guidance of $602–610 million. What has moved is the price and the targets. The shares rose 49.4% over three months to the 26 October 2026 close. Citizens maintained a Market Outperform rating and raised its target to $68 on 21 October 2026. The odds of beating the S&P 500 over the next three months look no better than even, because the price already reflects much of the good news.

The narrative is maturing: the S&P SmallCap 600 inclusion took effect before trading on 21 September 2026, the shares have since made new highs, and analysts are still lifting targets, but no new company results have appeared since 23 July 2026. The 14-day relative strength index (RSI) was 74.6 on 26 October 2026, a reading above 70 that is conventionally read as stretched.

Bullish and bearish views on AtriCure, Inc.

The bull case on AtriCure, Inc. (ATRC), in brief: Profitability is now reported. The bear case: The price is above older targets.

Bull case

• Profitability is now reported. On 23 July 2026, AtriCure reported second-quarter net income of $9.0 million and adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) of $27.3 million. It guided adjusted earnings per share to $0.24–$0.32 for fiscal 2026. Q2 2026 release
• Pain management is growing on volume. Second-quarter pain-management revenue rose 27.8% year over year to $27.1 million. At the 8 September 2026 Wells Fargo conference, Chief Financial Officer Angela Wirick attributed most of that growth to procedure volume rather than pricing.
• Analyst targets keep rising. Citizens raised its target to $68 on 21 October 2026. Stifel reiterated $65 on 17 September 2026, Needham raised its target from $45 to $64 on 2 September 2026, and BTIG raised its target to $63 on 12 October 2026.
• A clinical catalyst is queued. Needham's 2 September 2026 note expects enrolment in the BoxX-NoAF trial to finish by end-2026, with first results in the first half of 2027.

Bear case

• The price is above older targets. The average analyst target was $53.30 across one Strong Buy, seven Buy and four Hold ratings on 23 September 2026, per The Stock Observer. The $61.08 close on 26 October 2026 is above that figure and above Freedom Capital Markets' $57 target from 2 October 2026.
• One rating cut came during the rally. Freedom Capital moved to Hold on 2 October 2026 while raising its target, a sign that at least one firm judged the good news absorbed.
• Insiders sold into strength. Karl S. Regina E. Groves sold 5,313 shares at $54.22 on 11 September 2026, per The Stock Observer citing insider filings. Officer sales run under pre-scheduled Rule 10b5-1 plans.
• Management described uneven demand. On 8 September 2026, Wirick acknowledged continued pressure in hybrid ablation and execution problems internationally. The trailing price-to-earnings ratio was 284.38 on 23 September 2026, per The Stock Observer, because earnings are only now emerging.
• Appendage management is contested. The franchise produced $51.6 million of the $153.6 million of second-quarter revenue, and it faces Medtronic's Penditure and Edwards' ECLIPTIS devices.

Price setup

The adjusted daily close of $61.08 on 26 October 2026 equals the 52-week high, so the shares sit at the top of their one-year range. The prior reference was an intraday one-year high of $60.99 on 23 September 2026 and a close of $56.87 on 13 October 2026, so the shares have advanced since the mid-October pullback. The 14-day RSI of 74.6 on 26 October 2026 compares with 42.0 on 13 October 2026.

Several crowding markers are observable. The shares trade at a new high one week before earnings. Insider sales occurred at $48.89 and $54.22, well below the current price. Index inclusion in September added a mechanical source of demand that has already been absorbed. The price is below the Citizens, Stifel, Needham and BTIG targets and above the September average target and Freedom Capital's.

Under the standing invalidation condition, a weekly close below $47 would undo the September re-rating.

Catalysts, next 30 days

• ~31 December 2026, est.: Targeted completion of BoxX-NoAF trial enrolment, per Needham's 2 September 2026 note. This falls outside the 30-day window but carries the clinical half of the case.

Elapsed catalysts

• 3 November 2026: Third-quarter 2026 results, with a webcast at 4:30 p.m. Eastern, per a financial-news aggregator citing the company. The date does not yet appear in an AtriCure filing. The report tests the $602–610 million fiscal 2026 revenue range and the pain-management growth rate against 27.8% in the second quarter. (passed 3d ago)

What would change the view

The case breaks if the third-quarter report cuts fiscal 2026 revenue guidance below the $602 million floor set on 23 July 2026, or if pain-management growth falls well below the 27.8% year-over-year rate of the second quarter. Appendage-management revenue declining year over year, or management describing account losses to Medtronic or Edwards devices, would also weaken it. A slip in BoxX-NoAF enrolment past the end of 2026 would damage the clinical half.

On price, a weekly close below $47 would undo the September re-rating. A report that raises guidance, with pain-management growth holding near the second-quarter rate, would strengthen the case for a higher rating.

What it trades with

AtriCure trades with small-cap and mid-cap medical-device shares, and the September S&P SmallCap 600 inclusion ties part of its flow to index demand. Its revenue depends on elective cardiac-surgery volumes and hospital staffing, so it responds to hospital procedure-scheduling data more than to broad technology or rate-driven moves. Competitors Medtronic and Edwards Lifesciences report on their own schedules, and their appendage-management commentary can move AtriCure shares.